Lv1
30 积分 2023-12-18 加入
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results
5天前
已完结
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
13天前
已完结
Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis
13天前
已完结
ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies
16天前
已完结
‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
16天前
已完结
Tumour-infiltrating lymphocyte cancer therapy nears FDA finish line
1个月前
已完结
Entering a New Era of TIL Cell Therapy Innovation
1个月前
已完结
IL-15 as a key regulator in NK cell-mediated immunotherapy for cancer: From bench to bedside
1个月前
已完结
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
1个月前
已完结
Ponsegromab for the Treatment of Cancer Cachexia
2个月前
已完结
皖公网安备34019202002308
